Year: 2026
Type: article
Abstract: TAIBRN ВНУТРЕННИЕ БОЛЕЗНИ УДК 616.33 Фармакологические подходы к терапии метаболически ассоциированного стеатогепатита А. А. Нурдинова 1 , Д. М. Полянская 1 , Д. И. Рамазанова 2 , Д. А. Хашхаева 3 , О. Г. Глушкова 4 1 Первый Санкт-Петербургский государственный медицинский университет им.академика И. П. Павлова, Российская Федерация, 197022, Санкт-Петербург, ул.Льва Толстого, 6-8 2 Областная клиническая больница № 2 Тюменской области, Российская Федерация, 625039, Тюмень, ул.Мельникайте, 75 3 Ростовский государственный медицинский университет, Российская Федерация, 344022, Ростов-на-Дону, пер.Нахичеванский, 29 4 Казанский государственный медицинский университет, Российская Федерация, 420012, Казань, ул.Бутлерова, 49 Вестник СПбГУ.Медицина.2026.Т. 21.Вып. 1 nisms of MASH, including insulin resistance, lipotoxicity, and chronic inflammation, are reviewed.The current state of pharmacotherapy aimed at correcting these mechanisms is clarified, with a focus on drugs targeting various receptors and anti-inflammatory strategies.The efficacy of agents acting on various receptors has been evaluated: FXR agonists (Farnesoid X receptor) (obeticholic acid), PPAR agonists (Peroxisome proliferator-activated receptor) (lanifibranor), GLP-1 agonists (Glucagon-like peptide-1) (semaglutide, tirzepatide), as well as anti-inflammatory agents.Clinical studies are presented, confirming the efficacy of drugs from various classes in improving liver histological parameters, as well as in reducing steatosis, inflammation, and fibrosis.The article also discusses the clinical limitations related to the safety and long-term effectiveness of therapy, emphasizing the need for further research to optimize dosages and patient selection criteria.The results of combination therapy and its synergistic effects on lipid metabolism, insulin sensitivity, and inflammation are discussed.The inclusion of drugs with different mechanisms of action in therapy can significantly enhance the effectiveness of MASH treatment, which requires further studies and dosage clarification.Pharmacological therapy for MASH is one of the directions of modern hepatology, especially given the limited effectiveness of non-pharmacological methods.
Language: Russian
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7223522622
